Geron RYTELO LR-MDS Study Results

Geron Corporation announced that the first real-world evidence study of its drug RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The investigator-sponsored study, conducted at the H. Lee Moffitt Cancer Center & Research Institute, showed safety and clinical efficacy consistent with the Phase 3 IMerge trial in a broader patient population. The retrospective portion of the study, involving 40 patients, reported a red blood cell transfusion independence rate of 37.5% lasting at least eight weeks, with a safety profile consistent with known data. These findings support RYTELO (imetelstat) as a preferred treatment option for LR-MDS patients with significant transfusion burden. Geron Corporation will also present additional data on its myelofibrosis and AML clinical programs at EHA 2026 and the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved by the United States — Food and Drug Administration (FDA) and the International — European Commission.